Short Squeeze And Gap Fill To Come - GME, AMC, EXPR, OTRK, KOSS, LIVE

Meme stocks and short squeeze candidates remain bullish after today. The star of the show today was OTRK which went up 17% to $35.18. This was the highest close it has had since its big gap down on March 1. Short interest data pulled from Yahoo Finance was updated for numbers up to the end of February:

These stats are posted exactly as is from Yahoo Finance and we're aware that the short % doesn't equate to the short interest divided by float. GME remains the top target, though its short interest as a percentage of the float did decrease from 60% to 52%. OTRK's increased slightly to 32% from 30% and remains the second highest shorted stock of the six. KOSS' short interest doubled to 21% so that's another one to watch. 

A chart of OTRK's recent performance really outlines its short squeeze and gap fill potential:




 













The stock has a white candlestick extending well above the highs of the gap down made on March 1. This is really important because now it's in the zone where it can fill that gap quickly. The stock lost as much as it did that day after news of it losing its largest client, but financial results released earlier this week are being very well received by the market, with many thinking it can overcome this loss and still see strong growth going forward. 

LIVE remains a dark horse play. The short interest is low, but it doesn't really need short interest because of its extremely small float of only 1.27 million shares. KOSS has generally had a low short interest but that didn't stop the stock from running to over $100 from $10. LIVE's float is less than half of KOSS. Also LIVE is the only one in the group that has earnings and a P/E ratio. Most P/E ratios are around 20 so LIVE being at only 6 makes the stock nearly four times undervalued. We think it can reach $100 to come more in line with average P/E ratio numbers. 

Comments

Post a Comment

Popular posts from this blog

The Two Best Biotech Short Squeeze Candidates And The Next Carvana

Image
With the market having recovered most of its recent drop to be near all-time highs once again, shorts have been destroyed and are in a desperate spot. Heavily shorted stocks like B. Riley Financial, Inc. (RILY), Globe Life Inc. (GL) and Carvana Co. (CVNA) have been on absolute tears. We have written about CVNA before , as well as the impact of CVNA's move on Root , Inc. (ROOT). When a stock is squeezing like CVNA, a related stock like ROOT will follow suit. Shorts are often shorting multiple related stocks. Most don't even hide it with Kerrisdale openly bragging about its poor track record. GL was another one that was attacked by shorts which we talked about as a gamma squeeze candidate that has worked out very well over the past three weeks.  In this market of short squeezes, we have identified two excellent biotech short squeeze candidates, ImmunityBio, Inc. (IBRX) and Soleno Therapeutics, Inc. (SLNO). IBRX is starting up the production and sale of its cancer drug ANKT...
Read more

The Next NVDA-Backed Runner and New Asian IPO Squeeze Play

Image
We have seen stocks like Super Micro Computer, Inc. (SMCI) and SoundHound AI, Inc. (SOUN) have incredible squeeze runs thanks to their connection to NVIDIA Corporation (NVDA). We think the next one will be Spire Global, Inc. (SPIR), which popped a week ago after it announced a collaboration with NVDA to enhance AI-driven weather prediction. A few day later it dropped on the announcement of a financing at $14, with the potential to raise $61 million if warrants at $14.50 are exercised. We think there is a good chance that NVDA got in on this financing, as it tends to invest in the companies it does these deals with when spreading AI across different sectors. One such recent example was with Recursion Pharmaceuticals, Inc. (RXRX) for AI in drug development.  It looks like SPIR didn't really need this financing as it has enough cash and looks like it will be cash flow and net income positive in 2024. This financing was of a strategic nature, not something led by broker...
Read more

Forget about CVNA, PLCE is the Next Major Short Squeeze Play

Image
 Back in June, we called out Kerrisdale Capital and its short on Carvana Co. (CVNA) in our piece " Carvana: The Gamma Squeeze is Real, Time to Bankrupt Kerrisdale ". Kerrisdale has a history of calling one bad short after another, creating a squeeze on all of its positions as the firm and its associates face liquidity crises. Kerrisdale is once again on a cold streak as its short on Altimmune, Inc. (ALT) simultaneously blew up just as CVNA headed from $70 to $80 this week.  However, we think CVNA is done for now. Recall that in June after the initial spike to nearly $30, the stock pulled back to $20 before hitting $40 in the next month. People who are riding weekly call options aren't likely to cash in. CVNA looks headed to the mid to low $60's to close the gap that currently exists in the $62 to $66 area before resuming any further rise. Kerrisdale created an artificial short squeeze with its report, but now that both ALT and CVNA have come down from their weekly hig...
Read more